NPCE (Neuropace, Inc. Common Stock) Stock Analysis - News
Neuropace, Inc. Common Stock (NPCE) is a publicly traded Healthcare sector company. As of May 21, 2026, NPCE trades at $16.25 with a market cap of $545.16M and a P/E ratio of -24.63. NPCE moved +2.43% today. Year to date, NPCE is +2.59%; over the trailing twelve months it is -9.56%. Its 52-week range spans $5.45 to $19.60. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces NPCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in NPCE news today?
NeuroPace Q1 Sales Up 19.5%, Guidance Raised to 21–23% with $20 Price Target: NeuroPace reported a Q1 adjusted loss of $0.13 per share on $22.1 million revenue, driven by a 19.5% increase in RNS System sales to $21.7 million. The company raised its full-year 2026 RNS System sales growth target to 21–23% and saw its price target lifted to $20.
NeuroPace Q1 Sales Up 19.5%, Guidance Raised to 21–23% with $20 Price Target: NeuroPace reported a Q1 adjusted loss of $0.13 per share on $22.1 million revenue, driven by a 19.5% increase in RNS System sales to $21.7 million. The company raised its full-year 2026 RNS System sales growth target to 21–23% and saw its price target lifted to $20.
Does Rallies summarize NPCE news?
Yes. Rallies summarizes NPCE news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is NPCE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NPCE. It does not provide personalized investment advice.
